Nonvalvular atrial fibrillation and stroke

Shinichi Takahashi

Research output: Contribution to journalReview article

2 Citations (Scopus)

Abstract

Cardioembolism, responsible for approximately one-third of cerebral infarctions in Japan, causes serious cerebral infarction with poor prognosis. Nonvalvular atrial fibrillation (NVAF) is the most important cause of cardioembolism. Both the occurrence of NVAF and the frequency of its progression to cerebral infarction increase with age. Timely introduction of warfarin depending on the presence or absence of risk factors for cerebral infarction, including age, is essential for the prevention of cardioembolism. At present, monitoring based on PT-INR is indispensable for warfarin therapy. Oral direct thrombin inhibitors seem promising as a future therapy achieving a stable anticoagulation effect by the use of a fixed dose. Angiotensin II receptor blockers (ARBs) are expected to be effective in preventing new atrial fibrillation and maintaining sinus rhythm, offering a promise of clinical usefulness in reducing cerebral infarction, including the prevention of relapse.

Original languageEnglish
Pages (from-to)119-124
Number of pages6
JournalJapan Medical Association Journal
Volume49
Issue number3
Publication statusPublished - 2006 Mar 1

Keywords

  • Angiotensi II receptor blocker (ARB)
  • Aspirin
  • Cardioembolism
  • PT-INR
  • Warfarin
  • Ximelagatran

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Nonvalvular atrial fibrillation and stroke'. Together they form a unique fingerprint.

  • Cite this